Tempus AI’s chief accounting officer sells shares worth $290,265

Ryan M. Bartolucci, Chief Accounting Officer at Tempus AI , Inc. (NASDAQ:TEM), recently sold a significant portion of company stock, according to a recent SEC filing. On February 5, Bartolucci sold 1,858 shares of Class A Common Stock at an average price of $67.57, amounting to approximately $125,545. This transaction was part of a mandatory sale to cover tax obligations related to restricted stock units. The sale comes amid strong momentum for TEM shares, which have surged 92.51% year-to-date. InvestingPro data indicates the stock is currently trading in overbought territory.

On the following day, February 6, Bartolucci executed another sale, disposing of 2,320 shares at a price of $71 per share, totaling around $164,720. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on June 14, 2024. The company, currently valued at $10.23 billion, maintains a healthy liquidity position with a current ratio of 2.69.

Following these transactions, Bartolucci holds 53,059 shares of Tempus AI. These sales were part of a structured plan and not discretionary, as noted in the filing. InvestingPro analysis reveals 8 additional key insights about TEM’s financial health and valuation metrics.

In other recent news, Tempus AI has been making significant strides in the AI healthcare sector. The company recently upgraded its stock rating and increased the price target to $74, as reported by TD Cowen. This upgrade followed Tempus AI’s acquisition of Ambry Genetics, which has added a profitable germline testing laboratory with over $300 million in revenue to Tempus AI’s portfolio. Analysts at TD Cowen believe this strategic move will enhance Tempus AI’s product offerings and open up new markets.

In addition to the acquisition, Tempus AI has launched a personal health concierge app named Olivia. This application aims to centralize patient health data and provide actionable AI-driven insights, furthering the company’s commitment to improving patient outcomes through technology. Olivia’s features include synthesizing patient data into a comprehensive profile and summarizing physician appointments, among others.

Recent developments also include a partnership between Genialis and Tempus AI. Genialis, a company specializing in RNA biomarkers, has entered a multi-year agreement with Tempus AI to validate new RNA-based biomarker algorithms. This collaboration is expected to contribute to the advancement of precision medicine and patient care sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.